165 related articles for article (PubMed ID: 20178716)
1. NMR identifies atherogenic lipoprotein abnormalities in early diabetic nephropathy that are unrecognized by conventional analysis.
Al-Shahrouri HZ; Ramirez P; Fanti P; Abboud H; Lorenzo C; Haffner S
Clin Nephrol; 2010 Mar; 73(3):180-9. PubMed ID: 20178716
[TBL] [Abstract][Full Text] [Related]
2. Heterogeneous properties of intermediate- and low-density lipoprotein subpopulations.
Srisawasdi P; Vanavanan S; Rochanawutanon M; Pornsuriyasak P; Tantrakul V; Kruthkul K; Kotani K
Clin Biochem; 2013 Oct; 46(15):1509-15. PubMed ID: 23830843
[TBL] [Abstract][Full Text] [Related]
3. Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy.
Jenkins AJ; Lyons TJ; Zheng D; Otvos JD; Lackland DT; McGee D; Garvey WT; Klein RL;
Kidney Int; 2003 Sep; 64(3):817-28. PubMed ID: 12911531
[TBL] [Abstract][Full Text] [Related]
4. Increased large VLDL and small LDL particles are related to lower bilirubin in Type 2 diabetes mellitus.
Dullaart RP; de Vries R; Lefrandt JD
Clin Biochem; 2014 Nov; 47(16-17):170-5. PubMed ID: 25149194
[TBL] [Abstract][Full Text] [Related]
5. Higher serum betatrophin level in type 2 diabetes subjects is associated with urinary albumin excretion and renal function.
Chen CC; Susanto H; Chuang WH; Liu TY; Wang CH
Cardiovasc Diabetol; 2016 Jan; 15():3. PubMed ID: 26739836
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.
Soedamah-Muthu SS; Chang YF; Otvos J; Evans RW; Orchard TJ;
Diabetologia; 2003 May; 46(5):674-82. PubMed ID: 12743701
[TBL] [Abstract][Full Text] [Related]
7. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.
Garvey WT; Kwon S; Zheng D; Shaughnessy S; Wallace P; Hutto A; Pugh K; Jenkins AJ; Klein RL; Liao Y
Diabetes; 2003 Feb; 52(2):453-62. PubMed ID: 12540621
[TBL] [Abstract][Full Text] [Related]
8. Extended-release niacin/laropiprant effects on lipoprotein subfractions in patients with type 2 diabetes mellitus.
Bays H; Giezek H; McKenney JM; O'Neill EA; Tershakovec AM
Metab Syndr Relat Disord; 2012 Aug; 10(4):260-6. PubMed ID: 22400810
[TBL] [Abstract][Full Text] [Related]
9. Influence of early diabetic nephropathy on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition.
Winocour PH; Durrington PN; Bhatnagar D; Ishola M; Mackness M; Arrol S
Atherosclerosis; 1991 Jul; 89(1):49-57. PubMed ID: 1772471
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein particles and incident type 2 diabetes in the multi-ethnic study of atherosclerosis.
Mackey RH; Mora S; Bertoni AG; Wassel CL; Carnethon MR; Sibley CT; Goff DC
Diabetes Care; 2015 Apr; 38(4):628-36. PubMed ID: 25592196
[TBL] [Abstract][Full Text] [Related]
11. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.
Festa A; Williams K; Hanley AJ; Otvos JD; Goff DC; Wagenknecht LE; Haffner SM
Circulation; 2005 Jun; 111(25):3465-72. PubMed ID: 15983261
[TBL] [Abstract][Full Text] [Related]
12. Hyperapobetalipoproteinemia with compositional abnormality of LDL and IDL, a characteristic lipoprotein alteration in essential hypertension.
Ryomoto KI; Suzuki M; Kanazawa A; Hasegawa M; Kimura Y; Yamamura T; Harano Y
Am J Hypertens; 2000 Jun; 13(6 Pt 1):617-24. PubMed ID: 10912744
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes.
Colhoun HM; Otvos JD; Rubens MB; Taskinen MR; Underwood SR; Fuller JH
Diabetes; 2002 Jun; 51(6):1949-56. PubMed ID: 12031985
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women.
Mora S; Otvos JD; Rosenson RS; Pradhan A; Buring JE; Ridker PM
Diabetes; 2010 May; 59(5):1153-60. PubMed ID: 20185808
[TBL] [Abstract][Full Text] [Related]
15. Pathophysiology of Diabetic Dyslipidemia.
Hirano T
J Atheroscler Thromb; 2018 Sep; 25(9):771-782. PubMed ID: 29998913
[TBL] [Abstract][Full Text] [Related]
16. Carbamylated Lipoproteins and Progression of Diabetic Kidney Disease.
Tan KCB; Cheung CL; Lee ACH; Lam JKY; Wong Y; Shiu SWM
Clin J Am Soc Nephrol; 2020 Mar; 15(3):359-366. PubMed ID: 32075807
[TBL] [Abstract][Full Text] [Related]
17. Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia.
Othman RA; Myrie SB; Mymin D; Roullet JB; Steiner RD; Jones PJH
Atherosclerosis; 2017 May; 260():27-33. PubMed ID: 28340366
[TBL] [Abstract][Full Text] [Related]
18. High prevalence of small LDL particles in non-insulin-dependent diabetic patients with nephropathy.
Hirano T; Naito H; Kurokawa M; Ebara T; Nagano S; Adachi M; Yoshino G
Atherosclerosis; 1996 Jun; 123(1-2):57-72. PubMed ID: 8782837
[TBL] [Abstract][Full Text] [Related]
19. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk.
Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L
Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668
[TBL] [Abstract][Full Text] [Related]
20. Atherogenic lipoprotein changes in diabetic nephropathy.
Shoji T; Emoto M; Kawagishi T; Kimoto E; Yamada A; Tabata T; Ishimura E; Inaba M; Okuno Y; Nishizawa Y
Atherosclerosis; 2001 Jun; 156(2):425-33. PubMed ID: 11395040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
